A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2012; you can also visit the original URL.
The file type is
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positive acute lymphatic leukemia. The efficacy of imatinib has geared up further research into developmentpmid:16800347 fatcat:havoph3rarg4jldrq7ws7okobm